Modelling familial dysautonomia in human induced pluripotent stem cells

Modelling familial dysautonomia in human induced pluripotent stem cells.

Induced pluripotent stem (iPS) cells have considerable promise as a novel tool for modelling human disease and for drug discovery. While the generation of disease-specific iPS cells has become routine, realizing the potential of iPS cells in disease modelling poses challenges at multiple fronts. Such challenges include selecting a suitable disease target, directing the fate of iPS cells into sy...

Induced Pluripotent Stem Cells: Challenges and Opportunities

Regenerative capacity of mammals is limited and can rarely regenerate a specific organ or tissue fully. Due to these limitations, regenerative medicine seeks efficient and safe cell sources for regeneration of damaged tissues and organs or treatment for incurable diseases. Human embryonic stem cells (HESCs) hold two important properties called self renewal and pluripotency. However, the use of ...

Induced pluripotent stem cells for modelling human diseases.

Research into the pathophysiological mechanisms of human disease and the development of targeted therapies have been hindered by a lack of predictive disease models that can be experimentally manipulated in vitro. This review describes the current state of modelling human diseases with the use of human induced pluripotent stem (iPS) cell lines. To date, a variety of neurodegenerative diseases, ...

Human-Induced Pluripotent Stem Cells

Human-Induced Pluripotent Stem Cells The ability to reprogram adult mammalian somatic cells to a pluripotent state has proven to be a paradigm shifting discovery. In 2007, this reprogramming technology was translated to the engineering of human-induced pluripotent stem cells (hiPSCs) using skin fibroblasts by both the Yamanaka (transduction of c-Myc, Oct3/4, SOX2, and Klf4) and Thomson (transdu...

Human Testis–Derived Pluripotent Cells and Induced Pluripotent Stem Cells